treatment considerations for ighv-unmutated and mutated cll
Published 2 years ago • 1.4K plays • Length 2:31Download video MP4
Download video MP3
Similar videos
-
2:08
the differences in outcomes and treatment in cll patients with mutated and unmutated ighv
-
3:55
the origins of mutated and unmutated cll
-
2:20
treatment approaches for mutated and unmutated cll
-
1:50
the impact of ighv mutational status in treatment decisions in cll
-
2:32
ifcg for first-line treatment of ighv-mutated cll
-
2:27
the importance of tp53 & ighv testing before treatment initiation in cll
-
2:59
reducing the risks of chemotherapy in ighv-mutated cll
-
1:43
long-term outcomes of the ifcg regimen for firstline treatment of patients with ighv-mutated cll
-
2:02
the prognostic impact of tp53 and ighv status in the era of targeted therapies in cll
-
1:07
testing for ighv and tp53 mutations to guide treatment decisions in cll
-
5:03
ighv-mutated vs ighv-unmutated cll | what’s the difference?
-
1:11
the prognostic value of ighv mutational status with continuous vs time-limited therapy in cll
-
1:35
ifcg: a promising new regimen for treating ighv-mutated cll
-
1:04
defining high-risk cll: known and emerging mutations
-
1:29
the importance of treatment sequencing in cll
-
1:14
cll: ighv mutational status
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
1:28
the future of cll treatment
-
2:12
the impact of genetic abnormalities on treatment decisions in cll